Codiak to Present New Preclinical Data on exoASO™-STAT6 and exoASO-C/EBPβ at AACR 2020 Virtual Annual Meeting II (June 22-24); Evidence of Effectiveness Versus Hepatocellular Carcinoma; Registration for AACR Meeting Is Free

Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, has announced that it will present new preclinical data on its exoASO-STAT6 and exoASO-C/EBPβ programs via an oral presentation at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II (June 22-24) ( The Codiak oral presentation will be delivered on Tuesday, June 23, 2020, from 9:35-9:50 AM ET. Registration for the AACR virtual meeting is free. Codiak’s exoASO program utilizes its proprietary engEx™ Platform to engineer exosomes exogenously loaded with an antisense oligonucleotide (ASO). These exosomes are designed to selectively reprogram M2 immunosuppressive macrophages to an M1 pro-inflammatory phenotype by targeting and decreasing the expression of the immunosuppressive transcription factors STAT6 and C/EBPb. “These new data are encouraging because they demonstrate that both exoASO-STAT6 and exoASO-C/EBPβ showed significant efficacy when administered intravenously in an aggressive orthotopic model of hepatocellular carcinoma,” said Sriram Sathy, PhD, Senior Vice President, Preclinical Development at Codiak BioSciences. “We are excited to continue to advance this program through IND-enabling preclinical studies.” The oral presentation is titled “Genetic Reprogramming of Tams by Engineered Exosomes Results in Potent Single Agent Anti-Tumor Activity,” and it will be presented on Tuesday, June 23, from 9:35-9:50 AM in the “Novel Immunotherapies and Mechanisms” session. This oral presentation has abstract number 4723 and presentation number 5696.
Login Or Register To Read Full Story